Study on Atorvastatin for Patients with Early Breast Cancer

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called atorvastatin in patients with breast cancer. Atorvastatin is a type of medication known as a statin, which is commonly used to lower cholesterol levels. In this study, it is being tested to see if it can help improve outcomes for patients with early-stage breast cancer. The trial involves comparing the standard treatment for breast cancer, which may include surgery, chemotherapy, or hormone therapy, with the same standard treatment plus atorvastatin. Some participants will receive atorvastatin, while others will receive a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to determine if adding atorvastatin to the standard treatment can improve the time patients remain free from invasive breast cancer. This is known as invasive disease-free survival. The study will also look at other outcomes, such as overall survival and safety, to ensure that atorvastatin is safe and effective for use in this context. Participants in the study will take atorvastatin or a placebo daily for up to two years, and their health will be monitored regularly to track the progress of their breast cancer and any side effects they may experience.

This trial is designed for women with early-stage breast cancer who are receiving or have recently received standard treatments. The study aims to provide valuable information on whether atorvastatin can be a beneficial addition to the current treatment options for breast cancer, potentially leading to better outcomes for patients in the future.

1 joining the study

Upon joining the study, the patient must provide written informed consent. This is a formal agreement to participate, ensuring understanding of the study’s purpose and procedures.

2 randomization

The patient is randomly assigned to one of two groups: one receiving standard therapy plus a placebo, and the other receiving standard therapy plus atorvastatin.

3 medication administration

If assigned to the atorvastatin group, the patient will take 80 mg of atorvastatin daily. This medication is taken orally in the form of a film-coated tablet.

The duration of atorvastatin administration is two years.

4 monitoring and follow-up

Throughout the study, the patient’s health and response to treatment are monitored. This includes regular check-ups to assess the effectiveness and safety of the treatment.

The primary focus is on invasive disease-free survival, which measures the time until the first occurrence of specific cancer-related events.

5 study completion

The study is estimated to end by January 1, 2045. At this point, the final analysis of the collected data will be conducted to evaluate the outcomes of the treatment.

Who Can Join the Study?

Must be a woman with breast cancer that is sensitive to a hormone called estrogen.
Should be a candidate for (neo)adjuvant systemic therapy, which is treatment given before or after the main treatment to help improve outcomes, or have received no more than 3 years of adjuvant endocrine therapy, which is hormone therapy given after the main treatment to lower the risk of cancer returning.
Must be older than 18 years.
Should have a performance status of ECOG ≤ 2, which means the patient is able to carry out all self-care but is unable to carry out any work activities; up and about more than 50% of waking hours.
Must provide written informed consent before joining the study, following international and local guidelines.

Who Cannot Join the Study?

Patients who are not diagnosed with breast cancer cannot participate.
Only female patients are eligible; male patients cannot participate.
Patients who are part of a vulnerable population, meaning those who might need special protection or care, are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Sydvestjysk Sygehus	Esbjerg	Denmark

Other Sites

Site Name	City	Country
Næstved Hospital	Næstved	Denmark
Odense University Hospital	Odense	Denmark
Sygehus Lillebaelt Vejle Sygehus	Vejle	Denmark
Aalborg University Hospital	Aalborg	Denmark
Region Midtjylland	Aarhus	Denmark
Rigshospitalet	Copenhagen	Denmark
Sygehus Soenderjylland Soenderborg	Aabenraa	Denmark
Hgwfxy Hcvzjgay	Herlev	Denmark
Hushsrac Hccgdcjl	Hillerød	Denmark

Trial status

Country	Status	Recruitment Start
Denmark	Not recruiting	14.01.2021

Trial locations

Investigated drugs:

Atorvastatin

Atorvastatin is a medication used in this clinical trial to see if it can help improve the survival of patients with early breast cancer. It is being tested to find out if it can prevent the cancer from coming back when used alongside standard cancer treatments.

Investigated diseases:

Breast cancer

Breast Cancer – Breast cancer is a disease where cells in the breast grow uncontrollably, forming a tumor that can often be felt as a lump. It typically begins in the ducts or lobules of the breast and can spread to other parts of the body if not treated. The progression of breast cancer can vary, with some tumors growing slowly and others rapidly. It may remain localized to the breast or spread to nearby lymph nodes and other organs. The disease is categorized into stages based on the size of the tumor and the extent of spread. Early detection and understanding of its progression are crucial for managing the disease effectively.

Trial ID:

2024-515404-39-00

NCT ID:

NCT04601116

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Atorvastatin for Patients with Early Breast Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?